Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients

Basit Öğe Kaydı
dc.authorwosidBozkurt, Ceyhun/AAL-5043-2021
dc.contributor.authorLeventoglu, Emre
dc.contributor.authorSahin, Gurses
dc.contributor.authorYesil, Sule
dc.contributor.authorBozkurt, Ceyhun
dc.contributor.authorYuksek, Nazmiye
dc.contributor.authorFettah, Ali
dc.contributor.authorToprak, Sule
dc.date.accessioned2024-05-19T14:45:59Z
dc.date.available2024-05-19T14:45:59Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjective: Neuroblastoma is one of the common tumors of childhood. The demonstration of new factors such as isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations will be important in the diagnosis and treatment. IDH1 and IDH2 mutations have been found in many types of cancer, such as malignant gliomas, acute myeloid leukemias, chondrosarcoma, and thyroid carcinoma. This study aimed to investigate the presence of IDH1 or IDH2 mutations in patients with neuroblastoma and to determine whether these mutations were different in terms of age, clinical findings, and response to treatment.Methods: Biopsy specimens of 25 patients with pediatric neuroblastoma patients were evaluated for IDH mutations. The clinical and laboratory features of the patients with/without mutation were retrospectively analyzed from a hospital database. Results: A total of 25 patients for whom genetic analysis could be performed were included in the study (60% male, n=15). The mean age was 32.2 +/- 25.9 months (3 days-96 months). IDH1 mutation was detected in 8 (32%) and IDH2 mutations in 5 (20%) patients. These mutations showed no statistically significant relationship with age, tumor localization, laboratory results, stage, and prognosis. However, in the case of IDH mutation, patients were diagnosed at the advanced stage.Conclusions: This study demonstrated the relationship between neuroblastoma and IDH mutation for the first time. Because to the fact that the mutation is very heterogeneous, it would be appropriate to conduct a larger series of patients in terms of the impact of the clinical significance of each mutation on the diagnosis and prognosis.en_US
dc.identifier.doi10.4274/MMJ.galenos.2023.48768
dc.identifier.endpage110en_US
dc.identifier.issn2149-2042
dc.identifier.issn2149-4606
dc.identifier.issue2en_US
dc.identifier.pmid37338860en_US
dc.identifier.scopus2-s2.0-85163646676en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage102en_US
dc.identifier.trdizinid1184490en_US
dc.identifier.urihttps://doi.org10.4274/MMJ.galenos.2023.48768
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1184490
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5413
dc.identifier.volume38en_US
dc.identifier.wosWOS:001109589300004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofMedeniyet Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNeuroblastomaen_US
dc.subjectIsocitrate Dehydrogenase Mutationen_US
dc.subjectPediatricsen_US
dc.titleIsocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu